Carla Coffin

cscoffin@ucalgary.ca


In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Pam Ford

Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody

Simmone D'Souza

HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis

David Wong

Biologiste Médical

Ronald Simeon

Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis

Richard Morrow

Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review

Moses Donkor

Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections

Desmond Osei

EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Yashasavi Sachar

HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING

Yashasavi Sachar

Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD

Dong Hyun (Danny) Kim

Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis

Thomas Michalak

Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Alexa Thompson

Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience

Sébastien Poulin

Functional cure of chronic HBV infection

David Wong

Using discrete field documentation in Epic EMR for clinical research of hepatitis B

David Wong

A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex

Archee Panwar

Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection

Layla Al-Yasiri

Chronic HBV infection in Toronto, Canada: Tale of two clinics

David Wong

Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.

Nana Frimpong

Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)

Justine Beghin

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study

Golasa Samadi Kochaksaraei

Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study

Golasa Samadi Kochaksaraei

Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening

Carla Osiowy

IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa

Loghman Salimzadeh

Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba

Carla Osiowy

Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Valeriya Zaborska

PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model

Hoda Poorbagher

G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections

Jessica Skoreyko

Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors

Kuldeep Kaur

Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort

Jean Makuza

Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time

Curtis Cooper

Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia

Abdulrhman Alamr

Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto

David Wong

Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges

Colina Yim

Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin

Kira Sviderskaia

Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy

Frank Hyun

Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement

Emma Kasinyabo

Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection

Muhammad Atif Zahoor

Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex

Mohaddeseh Pakzamir

Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots

Michelle Tang

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Kira Sviderskaia

Under Review

Profile Summary

Submission ID PRO873B1FRP
Name Kira Sviderskaia
Call Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission
Email Address svidersk@ualberta.ca
Title Small molecules approach in HBV treatment: preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubicin
Organization Department of Medicine, Division of Infectious Disease, University of Alberta
State/Province AB
City Edmonton

Session

Title Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin
Description

Background: Chronic HBV persists in cells in a form of cccDNA that incorporates a knot-like structure formed by G-rich sequences, a G-quadruplex(G4Q). G4Q in the pre-core promoter region is vital for viral transcription. Mithramycin and daunorubicin are FDA approved anti-cancer drugs that can bind to G4Q and displace transcription factors preventing transcription.
Purpose: This project aims to measure the efficacy of those drugs against HBV.
Methods: The optimal drug dose in HepG2-NTCP cells was determined with Alamar blue viability assay. Next, using an HBV pre-core promoter luciferase plasmid, the impact of the drugs on luciferase output was measured. Finally, drugs were tested in an HBV infection model.
Results: Both drugs have inhibitory effects on the pre-core promoter of HBV in luciferase model. Infection studies will follow.
Conclusion: These drugs are suggested to block the binding of transcription factors, and therefore can act as a blueprint for a novel HBV drug.
Track Hepatitis B (including HDV, HCV, HIV Co-infections) - Biomedical/Basic Science
Formats
Audiences

Co-Presenters

Name Jessica Skoreyko
Organization University of Alberta
State/Province Alberta
City Edmonton
Email jaskorey@ualberta.ca
Website N/A
Speaker Role
Name Vanessa Meier-Stephenson
Organization University of Alberta
State/Province
City
Email meierste@ualberta.ca
Website N/A
Speaker Role

Submit Review



Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?